Fusion Antibodies PLC (FAB) — Cash Flow-to-Debt Ratio
Fusion Antibodies PLC (FAB) has a Cash Flow-to-Debt Ratio of -0.53x as of September 2025, meaning its operating cash flow of GBX-575.00K could theoretically repay -1% of its total liabilities (GBX1.09 Million) in one year. Check FAB total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Fusion Antibodies PLC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Fusion Antibodies PLC across 11 annual periods. Also explore total assets of Fusion Antibodies PLC for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Fusion Antibodies PLC (2015–2025)
Year-by-year debt coverage analysis for Fusion Antibodies PLC. For market capitalisation and broader financial context, see Fusion Antibodies PLC (FAB) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.09x | GBX-1.36 Million | GBX654.00K | ▲ +26.1% |
| 2024 | -2.82x | GBX-1.77 Million | GBX627.00K | ▼ -51.0% |
| 2023 | -1.87x | GBX-1.75 Million | GBX939.00K | ▼ -597.2% |
| 2022 | -0.27x | GBX-330.00K | GBX1.23 Million | ▲ +74.8% |
| 2021 | -1.06x | GBX-1.15 Million | GBX1.08 Million | ▼ -686.2% |
| 2020 | -0.14x | GBX-166.00K | GBX1.23 Million | ▲ +89.1% |
| 2019 | -1.24x | GBX-1.10 Million | GBX888.53K | ▼ -1114.6% |
| 2018 | 0.12x | GBX77.19K | GBX633.59K | ▲ +246.8% |
| 2017 | -0.08x | GBX-37.37K | GBX450.22K | ▼ -109.9% |
| 2016 | 0.84x | GBX346.57K | GBX411.43K | ▲ +193.3% |
| 2015 | -0.90x | GBX-182.05K | GBX201.67K | — |